Metformin in Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis
In brief
Metformin linked to 36% lower kidney-failure risk in advanced CKD
A meta-analysis of 10 observational studies found metformin use was associated with a 36% lower risk of end-stage kidney disease in adults with type 2 diabetes and advanced chronic kidney disease. Links to fewer cardiovascular events or deaths were uncertain, and higher acidosis risk could not be ruled out; very low evidence certainty means the findings do not settle whether metformin is safe or beneficial in this group.
- Journal
- Diabetes, obesity & metabolism (Q1)
- Published
- 19 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Juan Pinilla, Felemez Arslan, Clara Campoverde, Federico Napoli, Zaraith Coy, Saria Hassan, et al.
- PMID
- 43058053
- DOI
- 10.1111/dom.71564
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 21 November 2026): Metformin safety and outcomes in advanced CKD
Abstract
AIMS: To evaluate associations of metformin exposure with all-cause mortality, major adverse cardiovascular events (MACE), end-stage kidney disease (ESKD) and lactic or metabolic acidosis in adults with Type 2 diabetes and advanced CKD (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2) not receiving chronic dialysis. MATERIALS AND METHODS: We searched PubMed, Scopus, Web of Science and Cochrane from inception through 5 September 2026 for observational cohort studies evaluating metformin exposure in this population. Comparator strategies included non-use, discontinuation and alternative glucose-lowering therapy. Data were synthesized using Bayesian random-effects models with empirical heterogeneity priors (primary) and frequentist random-effects models. Certainty of the evidence was assessed using the GRADE framework. RESULTS: Ten cohort studies were included. For ESKD, the pooled hazard ratio (HR) from the Bayesian analysis was 0.64 (95% CrI: 0.45-0.92; 99% posterior probability of HR < 1). Estimates for MACE (HR 0.88, 95% CrI: 0.72-1.08) and all-cause mortality (HR 0.89, 95% CrI: 0.73-1.10) were imprecise. Lactic or metabolic acidosis showed an increased-risk estimate with a wide CrI (HR 1.39, 95% CrI: 0.76-2.49). Certainty of the evidence was very low for all outcomes. CONCLUSIONS: For ESKD, the pooled Bayesian estimate was below the null, whereas estimates for all-cause mortality and MACE remained uncertain, and an increased risk of acidosis could not be excluded. Given the very low certainty of the evidence and the heterogeneity of treatment strategies, these findings should be interpreted with considerable caution. Further randomized or well-designed observational evidence using clearly defined treatment strategies is needed.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.